Anti-cav peptide analogue and corresponding cdna and its application

A technology of analogs and drugs, applied in the field of peptide analogs, can solve problems such as intima thickening, achieve the effect of promoting interaction, inhibiting development, and facilitating large-scale preparation

Active Publication Date: 2018-11-16
NANTONG TENGZHONG MACHINERY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, studies have shown that vascular smooth muscle cells (VSMC) can be activated during heart transplantation to synthesize extracellular matrix leading to intimal thickening

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-cav peptide analogue and corresponding cdna and its application
  • Anti-cav peptide analogue and corresponding cdna and its application
  • Anti-cav peptide analogue and corresponding cdna and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The present invention will be described in further detail below in conjunction with the accompanying drawings.

[0018] To achieve the above object, according to one aspect of the present invention, an anti-CAV polypeptide analogue is provided, the amino acid sequence of which is shown in SEQ NO.1 in the sequence listing. Anti-CAV peptide analogs are used to promote the interaction between TIMP-1 and MMP-14, inhibit the migration of VSMC after heart transplantation, and inhibit the development of CAV.

[0019] Correspondingly, the present invention also provides the application of the above-mentioned anti-CAV polypeptide analogs in the preparation of anti-angiopathic drugs of heart grafts.

[0020] Correspondingly, the present invention also provides the cDNA sequence of the above-mentioned anti-CAV polypeptide analogue, the sequence of which is shown in SEQ NO.2 in the sequence table.

[0021] Correspondingly, the present invention also provides the application of the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a polypeptide analog for resisting heart implant vasculopathy, and a corresponding cDNA (complementary deoxyribonucleic acid) and application thereof. On the basis of the establishment of the TIMP-1 and MMP-14 interaction structure field in CAV, the invention provides a method for producing a recombinant polypeptide analog myc HisA-TIMP-1[triangle102-217aa] by a gene engineering process. The polypeptide analog has the advantages of high expression efficiency and simple purification technique, and is beneficial to further large-scale preparation. The polypeptide analog can promote the interaction between TIMP-1 and MMP-14, inhibit the VSMC transfer after heart transplantation and inhibit the CAV from generation and development. The polypeptide analog can provide theoretical references for searching for effective intervention target spots for CAV and developing new therapeutic drugs. The polypeptide analog has very important development prospects for implementing long-term survival of heartmen after CAV clinical therapy.

Description

technical field [0001] The present invention relates to polypeptide analogs, in particular to an anti-CAV polypeptide analog, corresponding cDNA and application. Background technique [0002] Since the world's first successful heart transplant in 1967, more than 110,000 heart transplants have been registered worldwide. Heart transplantation has become the most effective way to treat various end-stage heart diseases. However, cardiac allograft vasculopathy (CAV), which is characterized by continuous thickening of the coronary intima of the transplanted heart, has become one of the main reasons for reducing the long-term survival rate of heart transplant recipients. [0003] At present, the exact pathogenesis of CAV is still unclear, and effective treatment measures are lacking. However, studies have shown that vascular smooth muscle cells (vascular smooth muscle cells, VSMCs) can be activated during heart transplantation to synthesize extracellular matrix and lead to intimal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/81A61K38/57A61P9/10C12N15/15
CPCA61K38/00C07K14/8146
Inventor 刘晓娟沈爱国颜大亮史加海
Owner NANTONG TENGZHONG MACHINERY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap